Evidence map›Paper›PMID 38906389›Full record

ArticleNeurotoxicology and teratology

Gestational buprenorphine-naloxone exposure and fetal neurobehavior.

Lauren M Jansson, Krystle McConnell, Martha L Velez, Nancy Spencer, Lorraine Milio, Jeannie Leoutsakos, Janet A DiPietro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotoxicology and teratology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lauren M JanssonJohns Hopkins University School of Medicine, Department of Pediatrics, Baltimore, MD 21224, USA. Electronic address: ljansson@jhmi.edu.
Krystle McConnellJohns Hopkins University School of Medicine, Department of Pediatrics, Baltimore, MD 21224, USA.
Martha L VelezJohns Hopkins University School of Medicine, Department of Pediatrics, Baltimore, MD 21224, USA.
Nancy SpencerJohns Hopkins Bayview Medical Center, Department of Nursing, Baltimore, MD 21224, USA.
Lorraine MilioJohns Hopkins University School of Medicine, Department of Gynecology and Obstetrics, Baltimore, MD 21224, USA.
Jeannie LeoutsakosJohns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, MD 21224, USA.
Janet A DiPietroJohns Hopkins Bloomberg School of Public Health, Department of Population, Family and Reproductive Health, Baltimore, MD 21224, USA.

Funding

Maternal buprenorphine-naloxone treatment during the perinatal period: Fetal and infant effectsR01DA041367 · NIDA · JOHNS HOPKINS UNIVERSITY · PI JANSSON, LAUREN M · 2017 to 2022
$3.0M
NIDA NIH HHS R01 DA041367
6 · The paper itself

Abstract

backgroundBuprenorphine-naloxone treatment may confer substantial benefits for the treatment of opioid use disorder (OUD) during pregnancy including lower risk for overdose/death, less diversion potential and reduced use of other substances. Treatment may also result in less severe Neonatal Abstinence Syndrome (NAS), but little is known about the effects of this medication on fetal neurodevelopment.

methodsThe purpose of the current study is to evaluate neurobehaviors among fetuses exposed to buprenorphine-naloxone at four time points over the second and third trimesters of gestation in pregnant women with OUD on buprenorphine-naloxone therapy. Sixty minutes of continuous fetal monitoring via fetal actocardiograph with a single wide array abdominal transducer took place at times of peak and trough buprenorphine-naloxone levels in 24 pregnant women. Data collection, which included measures of fetal heart rate and motor activity, was conducted between 24 and 36 weeks gestation, with the majority (84.6%) monitored at two or more gestational ages. Medication dose and other substance use was monitored throughout the study and infant NAS severity was assessed.

resultsFetal heart rate (FHR), FHR variability, accelerations in FHR, and motor activity were suppressed when buprenorphine-naloxone levels were at pharmacologic peak as compared to trough concentrations at 36 weeks, but not earlier in gestation. Maternal medication dose was unrelated to infant NAS severity.

conclusionsConclusions: There were evident subclinical fetal neurophysiological responses at times of peak maternal buprenorphine/naloxone levels in later gestation, similar to those previously described for buprenorphine only. Further studies evaluating the effects of these changes in fetal neurobehaviors on the longer-term infant development are needed.

Indexed as

Buprenorphine, Naloxone Drug CombinationHeart Rate, FetalOpioid-Related DisordersAdultBuprenorphineFemaleFetusHumansInfant, NewbornNarcotic AntagonistsNeonatal Abstinence SyndromeOpiate Substitution TreatmentPregnancyPregnancy ComplicationsPregnancy Trimester, ThirdPrenatal Exposure Delayed EffectsBuprenorphineBuprenorphine, Naloxone Drug CombinationNarcotic AntagonistsBuprenorphine-naloxoneFetal heart rateFetal movementFetal neurobehaviorMaternal opioid use disorderOpioid exposed dyad

Identifiers

PMID38906389
PMCPMC11300143

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.